These results also point to the combined use of PI3K inhibitors and ERBB1-3-neutralizing antibody mixtures, such as pan-HER/ERBB which can simultaneously block targeted ERBB receptors and ligands[59], as a potential therapy for BC tumours with HER2/PIK3CA co-alteration. This evidence concerns the gene PIK3CD and breast cancer.